A Phase I Study to Investigate the Effect of Hepatic Impairment on the  PK, Safety, and Tolerability of AZD2693

Study identifier:D7830C00008

ClinicalTrials.gov identifier:NCT05919069

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of AZD2693

Medical condition

Hepatic Impairment

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD2693

Sex

All

Estimated Enrollment

36

Study type

Interventional

Age

18 Years - 75 Years

Date

Study Start Date: 16 Jun 2023
Estimated Primary Completion Date: 01 Jul 2024
Estimated Study Completion Date: 01 Jul 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Other

Verification:

Verified 01 Jan 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria